» Articles » PMID: 312873

Genetic Control of Immune Response to Sperm Whale Myoglobin in Mice. II. T Lymphocyte Proliferative Response to the Synthetic Antigenic Sites

Overview
Journal J Immunol
Date 1979 Jul 1
PMID 312873
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The genetic control of T lymphocyte proliferative response to the five synthetic antigenic sites of myoglobin, two synthetic nonantigenic control peptides, and one "nonsense" peptide was determined in independent and recombinant strains of mice. In all the strains examined, the nonantigenic control peptides and the "nonsense" peptide did not invoke a response in myoglobin-primed mice. Further, when mice were not primed with whole myoglobin, no response was obtained with any of the antigenic sites. Haplotypes H-2d, H-2f, and H-2s are higher responders to sites 1 and 2, whereas haplotypes H-2d and H-2s are high responders to site 5. Response to site 3 may be controlled by a non-H-2-linked gene. Site 4 can stimulate H-2b and H-2k haplotypes that are nonresponders to the whole myoglobin. Studies with the recombinant strains suggested that Ir genes to sites 1 and 2 map in the I-A subregion and I-C subregion and were designated Ir-Mb-1,2(A) and Ir-Mb-1,2(C). Ir genes to sites 4 and 5 mapped only in the I-A subregion and were designated Ir-Mb-4(A) and Ir-Mb-5(A). These studies suggest that individual antigenic sites in a molecule are controlled by unique Ir genes.

Citing Articles

Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

Yoshida T, Okuda K, Xin K, Tadokoro K, Fukushima J, Toda S Clin Exp Immunol. 2001; 124(3):445-52.

PMID: 11472406 PMC: 1906078. DOI: 10.1046/j.1365-2249.2001.01540.x.


Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system.

Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M Immunology. 2001; 103(1):98-105.

PMID: 11380697 PMC: 1783209. DOI: 10.1046/j.1365-2567.2001.01201.x.


Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S J Virol. 1998; 72(6):4931-9.

PMID: 9573261 PMC: 110054. DOI: 10.1128/JVI.72.6.4931-4939.1998.


Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1.

Sasaki S, Fukushima J, Hamajima K, Ishii N, Tsuji T, Xin K Clin Exp Immunol. 1998; 111(1):30-5.

PMID: 9472658 PMC: 1904860. DOI: 10.1046/j.1365-2249.1998.00466.x.


HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.

Tsuji T, Fukushima J, Hamajima K, Ishii N, Aoki I, Bukawa H Immunology. 1997; 90(1):1-6.

PMID: 9038705 PMC: 1456706. DOI: 10.1046/j.1365-2567.1997.00117.x.